Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group

References

• Anderson, K. M. (2020), “simtrial: Clinical Trial Simulation for Time-to-Event Endpoints,” available at https://github.com/keaven/simtrial.
   Google Scholar
• Bartlett, J. W., Morris, T. P., Stensrud, M. J., Daniel, R. M., Vansteelandt, S. K., and Burman, C.-F. (2020), “The Hazards of Period Specific and Weighted Hazard Ratios,” Statistics in Biopharmaceutical Research, 12, 518–519. DOI: 10.1080/19466315.2020.1755722.
   PubMed Web of Science ®Google Scholar
• Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., and Barlesi, F. (2015), “Nivolumab Versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer,” New England Journal of Medicine, 373, 1627–1639. DOI: 10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Breslow, N. E., Edler, L., and Berger, J. (1984), “A Two-Sample Censored-Data Rank Test for Acceleration,” Biometrics, 40, 1049–1062. DOI: 10.2307/2531155.
   PubMed Web of Science ®Google Scholar
• Buckley, J., and James, I. (1979), “Linear Regression With Censored Data,” Biometrika, 66, 429–436. DOI: 10.1093/biomet/66.3.429.
   Web of Science ®Google Scholar
• Buyse, M. (2010), “Generalized Pairwise Comparisons of Prioritized Outcomes in the Two-Sample Problem,” Statistics in Medicine, 29, 3245–3257. DOI: 10.1002/sim.3923.
   PubMed Web of Science ®Google Scholar
• Callegaro, A., and Spiessens, B. (2017), “Testing Treatment Effect in Randomized Clinical Trials With Possible Nonproportional Hazards,” Statistics in Biopharmaceutical Research, 9, 204–211. DOI: 10.1080/19466315.2016.1257436.
   Web of Science ®Google Scholar
• Campbell, H., and Dean, C. (2014), “The Consequences of Proportional Hazards Based Model Selection,” Statistics in Medicine, 33, 1042–1056. DOI: 10.1002/sim.6021.
   PubMed Web of Science ®Google Scholar
• Chapman, J. W., O’Callaghan, C. J., Hu, N., Ding, K., Yothers, G. A., Catalano, P. J., Shi, Q., Gray, R. G., O’Connell, M. J., and Sargent, D. J. (2013), “Innovative Estimation of Survival Using Log-Normal Survival Modelling on ACCENT Database,” British Journal of Cancer, 108, 784–790. DOI: 10.1038/bjc.2013.34.
   PubMed Web of Science ®Google Scholar
• Chen, T.-T. (2013), “Statistical Issues and Challenges in Immuno-Oncology,” Journal for ImmunoTherapy of Cancer, 1, 1–9. DOI: 10.1186/2051-1426-1-18.
   PubMedGoogle Scholar
• Chi, Y., and Tsai, M.-H. (2001), “Some Versatile Tests Based on the Simultaneous Use of Weighted Logrank and Weighted Kaplan-Meier Statistics,” Communications in Statistics—Simulation and Computation, 30, 743–759. DOI: 10.1081/SAC-100107779.
   Web of Science ®Google Scholar
• Cohen, E. E. W., Souliéres, D., Le Tourneau, C., Dinis, J., Licitra, L., Ahn, M. J., Soria, A., Machiels, J. P., Mach, N., Mehra, R., and Burtness, B. (2019), “Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head-and-Neck Squamous Cell Carcinoma (KEYNOTE-040): A Randomised, Open-Label, Phase 3 Study,” The Lancet, 393, 156–167. DOI: 10.1016/S0140-6736(18)31999-8.
   PubMed Web of Science ®Google Scholar
• Cox, D. (1972), “Regression Models and Life-Tables,” Journal of the Royal Statistics Society, Series B, 34, 187–220. DOI: 10.1111/j.2517-6161.1972.tb00899.x.
   Web of Science ®Google Scholar
• Demets, D. L., and Lan, K. K. G. (1994), “Interim Analysis: The Alpha Spending Function Approach,” Statistics in Medicine, 13, 1341–1352. DOI: 10.1002/sim.4780131308.
   PubMed Web of Science ®Google Scholar
• Freidlin, B., and Korn, E. L. (2009), “Monitoring for Lack of Benefit: A Critical Component of a Randomized Clinical Trial,” Journal of Clinical Oncology, 27, 629–633. DOI: 10.1200/JCO.2008.17.8905.
   PubMed Web of Science ®Google Scholar
• Freidlin, B., and Korn, E. L. (2019), “Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?,” Journal of Clinical Oncology, 37, 3455–3459.
   PubMed Web of Science ®Google Scholar
• Genz, A. (1992), “Numerical Computation of Multivariate Normal Probabilities,” Journal of Computational and Graphical Statistics, 1, 141–149.
   Google Scholar
• Grambsch, P., and Theneau, T. (1994), “Proportional Hazards Tests and Diagnostics Based on Weighted Residuals,” Biometrika, 81, 515–526. DOI: 10.1093/biomet/81.3.515.
   Web of Science ®Google Scholar
• Guyot, P., Ades, A. E., Ouwens, M. J., and Welton, N. J. (2012), “Enhanced Secondary Analysis of Survival Data: Reconstructing the Data From Published Kaplan-Meier Survival Curves,” BMC Medical Research Methodology, 12, 9. DOI: 10.1186/1471-2288-12-9.
   PubMed Web of Science ®Google Scholar
• Harrington, D., and Fleming, T. (1982), “A Class of Rank Test Procedures for Censored Survival Data,” Biometrika, 69, 553–566. DOI: 10.1093/biomet/69.3.553.
   Web of Science ®Google Scholar
• Hasegawa, T. (2014), “Sample Size Determination for the Weighted Log-Rank Test With the Fleming–Harrington Class of Weights in Cancer Vaccine Studies,” Pharmaceutical Statistics, 13, 128–135. DOI: 10.1002/pst.1609.
   PubMed Web of Science ®Google Scholar
• Hasegawa, T. (2016), “Group Sequential Monitoring Based on the Weighted Log-Rank Test Statistic With the Fleming–Harrington Class of Weights in Cancer Vaccine Studies,” Pharmaceutical Statistics, 15, 412–419.
   PubMed Web of Science ®Google Scholar
• Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J. Y., Molina, J., Kim, J. H., Arvis, C. D., Ahn, M. J., and Majem, M. (2016), “Pembrolizumab Versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial,” The Lancet, 387, 1540–1550. DOI: 10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• ICH (1998), “International Conference on Harmonization (ICH E9): Statistical Principles for Clinical Trials,” available at https://www.ich.org/fileadmin/Public/_Web_Site/ICH/_Products/Guidelines/Efficacy/E9/Step4/E9/_Guideline.pdf.
   Google Scholar
• Kaplan, E., and Meier, P. (1958), “Nonparametric Estimation From Incomplete Observations,” Journal of the American Statistical Association, 53, 457–481. DOI: 10.1080/01621459.1958.10501452.
   Web of Science ®Google Scholar
• Karrison, T. (2016), “Versatile Tests for Comparing Survival Curves Based on Weighted Log-Rank Statistics,” Stata Journal, 16, 678–690. DOI: 10.1177/1536867X1601600308.
   Web of Science ®Google Scholar
• Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., Olivo, M. S., He, Y., Dutcus, C. E., and Cortes, J. (2015), “Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane,” Journal of Clinical Oncology, 33, 594–601. DOI: 10.1200/JCO.2013.52.4892.
   PubMed Web of Science ®Google Scholar
• Klein, J. P., Logan, B., Harhoff, M., and Andersen, P. K. (2007), “Analyzing Survival Curves at a Fixed Point in Time,” Statistics in Medicine, 26, 4505–4519. DOI: 10.1002/sim.2864.
   PubMed Web of Science ®Google Scholar
• Koehler, E., Brown, E., and Haneuse, S. J.-P. A. (2009), “On the Assessment of Monte Carlo Error in Simulation-Based Statistical Analyses,” The American Statistician, 63, 155–162. DOI: 10.1198/tast.2009.0030.
   PubMed Web of Science ®Google Scholar
• Lee, J. W. (1996), “Some Versatile Tests Based on the Simultaneous Use of Weighted Log-Rank Statistics,” Biometrics, 52, 721–725. DOI: 10.2307/2532911.
   Web of Science ®Google Scholar
• Lee, S.-H. (2007), “On the Versatility of the Combination of the Weighted Log-Rank Statistics,” Computational Statistics and Data Analysis, 51, 6557–6564. DOI: 10.1016/j.csda.2007.03.006.
   Web of Science ®Google Scholar
• Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., and Mukhopadhyay, P. (2020a), “Rejoinder to Letter to the Editor ‘The Hazards of Period Specific and Weighted Hazard Ratios’,” Statistics in Biopharmaceutical Research, 12, 520–521. DOI: 10.1080/19466315.2020.1825522.
   PubMed Web of Science ®Google Scholar
• Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., and Mukhopadhyay, P. (2020b), “Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis,” Statistics in Biopharmaceutical Research, 12, 187–198.
   Web of Science ®Google Scholar
• Logan, B. R., Klein, J. P., and Zhang, M.-J. (2008), “Comparing Treatments in the Presence of Crossing Survival Curves: An Application to Bone Marrow Transplantation,” Biometrics, 64, 733–740. DOI: 10.1111/j.1541-0420.2007.00975.x.
   PubMed Web of Science ®Google Scholar
• Logan, B. R., and Mo, S. (2015), “Group Sequential Tests for Long-Term Survival Comparisons,” Lifetime Data Analysis, 21, 218–240. DOI: 10.1007/s10985-014-9298-4.
   PubMed Web of Science ®Google Scholar
• Magirr, D., and Burman, C.-F. (2019), “Modestly Weighted Logrank Tests,” Statistics in Medicine, 38, 3782–3790. DOI: 10.1002/sim.8186.
   PubMed Web of Science ®Google Scholar
• Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., and Campos, D. (2007), “Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group,” Journal of Clinical Oncology, 25, 1960–1966. DOI: 10.1200/JCO.2006.07.9525.
   PubMed Web of Science ®Google Scholar
• Morris, T. P., White, I. R., and Crowther, M. J. (2019), “Using Simulation Studies to Evaluate Statistical Methods,” Statistics in Medicine, 38, 2074–2102. DOI: 10.1002/sim.8086.
   PubMed Web of Science ®Google Scholar
• Pepe, M. S., and Fleming, T. R. (1989), “Weighted Kaplan-Meier Statistics: A Class of Distance Tests for Censored Survival Data,” Biometrics, 45, 497–507. DOI: 10.2307/2531492.
   PubMed Web of Science ®Google Scholar
• Perón, J., Roy, P., Ozenne, B., Roche, L., and Buyse, M. (2016), “The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials,” JAMA Oncology, 2, 901–905. DOI: 10.1001/jamaoncol.2015.6359.
   PubMed Web of Science ®Google Scholar
• Peto, R., and Peto, J. (1972), “Asymptotically Efficient Rank Invariant Test Procedures,” Journal of the Royal Statistical Society, Series A, 135, 185–198. DOI: 10.2307/2344317.
   Web of Science ®Google Scholar
• Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., and Fléchon, A. (2018), “Atezolizumab Versus Chemotherapy in Patients With Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor211): A Multicentre, Open-Label, Phase 3 Randomised Controlled Trial,” The Lancet, 391, 748–757. DOI: 10.1016/S0140-6736(17)33297-X.
   PubMed Web of Science ®Google Scholar
• Powles, T., van der Heijden, M. S., Castellano, D., Galsky, M. D., Loriot, Y., Petrylak, D. P., Ogawa, O., Park, S. H., Lee, J. L., De Giorgi, U., and Bögemann, M. (2020), “Durvalumab Alone and Durvalumab Plus Tremelimumab Versus Chemotherapy in Previously Untreated Patients With Unresectable, Locally Advanced or Metastatic Urothelial Carcinoma (DANUBE): A Randomised, Open-Label, Multicentre, Phase 3 Trial,” The Lancet Oncology, 21, 1574–1588. DOI: 10.1016/S1470-2045(20)30541-6.
   PubMed Web of Science ®Google Scholar
• Prentice, R. L. (1978), “Linear Rank Tests With Right Censored Data,” Biometrika, 65, 167–179. DOI: 10.1093/biomet/65.1.167.
   Web of Science ®Google Scholar
• Putter, H., Sasako, M., Hartgrink, H. H., Van de Velde, C. J. H., and Van Houwelingen, J. C. (2005), “Long-Term Survival With Non-Proportional Hazards: Results From the Dutch Gastric Cancer Trial,” Statistics in Medicine, 24, 2807–2821. DOI: 10.1002/sim.2143.
   PubMed Web of Science ®Google Scholar
• Royston, P., and Parmar, M. K. (2011), “The Use of Restricted Mean Survival Time to Estimate the Treatment Effect in Randomized Clinical Trials When the Proportional Hazards Assumption Is in Doubt,” Statistics in Medicine, 30, 2409–2421. DOI: 10.1002/sim.4274.
   PubMed Web of Science ®Google Scholar
• Schemper, M. (1992), “Cox Analysis of Survival Data With Non-Proportional Hazard Functions,” Journal of the Royal Statistical Society, Series D, 41, 455–465. DOI: 10.2307/2349009.
   Google Scholar
• Schemper, M., Wakounig, S., and Heinze, G. (2009), “The Estimation of Average Hazard Ratios by Weighted Cox Regression,” Statistics in Medicine, 28, 2473–2489. DOI: 10.1002/sim.3623.
   PubMed Web of Science ®Google Scholar
• Therneau, T. M., and Grambsch, P. M. (2000), Modeling Survival Data: Extending the Cox Model, New York: Springer.
   Google Scholar
• Tian, L., Zhao, L., and Wei, L. J. (2014), “Predicting the Restricted Mean Event Time With the Subject’s Baseline Covariates in Survival Analysis,” Biostatistics, 15, 222–233. DOI: 10.1093/biostatistics/kxt050.
   PubMed Web of Science ®Google Scholar
• Tsiatis, A. A. (1982), “Repeated Significance Testing for a General Class of Statistics Used in Censored Survival Analysis,” Journal of the American Statistical Association, 77, 855–861. DOI: 10.1080/01621459.1982.10477898.
   Web of Science ®Google Scholar
• Uno, H., Claggett, B., Tian, L., Inoue, E., Gallo, P., Miyata, T., Schrag, D., Takeuchi, M., Uyama, Y., Zhao, L., and Skali, H. (2014), “Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis,” Journal of Clinical Oncology, 32, 2380–2385. DOI: 10.1200/JCO.2014.55.2208.
   PubMed Web of Science ®Google Scholar
• Wang, Y., Wu, H., Anderson, K., Roychoudhury, S., Hu, T., and Liu, H. (2019), “R package: nphsim,” available at http://github.com/keaven/nphsim.
   Google Scholar
• Xu, R., and O’Quigley, J. (2000), “Estimating Average Regression Effect Under Non-Proportional Hazards,” Biostatistics, 1, 423–439. DOI: 10.1093/biostatistics/1.4.423.
   PubMedGoogle Scholar
• Xu, Z., Park, Y., Zhen, B., and Zhu, B. (2018), “Designing Cancer Immunotherapy Trials With Random Treatment Time-Lag Effect,” Statistics in Medicine, 37, 4589–4609. DOI: 10.1002/sim.7937.
   PubMed Web of Science ®Google Scholar
• Xu, Z., Zhen, B., Park, Y., and Zhu, B. (2017), “Designing Therapeutic Cancer Vaccine Trials With Delayed Treatment Effect,” Statistics in Medicine, 36, 592–605. DOI: 10.1002/sim.7157.
   PubMed Web of Science ®Google Scholar
• Yang, S., and Prentice, R. (2010), “Improved Logrank-Type Tests for Survival Data Using Adaptive Weights,” Biometrics, 66, 30–38. DOI: 10.1111/j.1541-0420.2009.01243.x.
   PubMed Web of Science ®Google Scholar